- Home
- CARE vs ERAS Comparison
CARE vs ERAS Comparison
Compare CARE & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARE
- ERAS
- Stock Information
- Founded
- CARE 1974
- ERAS 2018
- Country
- CARE United States
- ERAS United States
- Employees
- CARE N/A
- ERAS N/A
- Industry
- CARE Major Banks
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CARE Finance
- ERAS Health Care
- Exchange
- CARE Nasdaq
- ERAS Nasdaq
- Market Cap
- CARE 456.8M
- ERAS 439.7M
- IPO Year
- CARE N/A
- ERAS 2021
- Fundamental
- Price
- CARE $19.38
- ERAS $2.43
- Analyst Decision
- CARE Buy
- ERAS Buy
- Analyst Count
- CARE 1
- ERAS 6
- Target Price
- CARE $22.00
- ERAS $3.83
- AVG Volume (30 Days)
- CARE 81.0K
- ERAS 2.3M
- Earning Date
- CARE 10-23-2025
- ERAS 11-11-2025
- Dividend Yield
- CARE N/A
- ERAS N/A
- EPS Growth
- CARE 154.06
- ERAS N/A
- EPS
- CARE 1.36
- ERAS N/A
- Revenue
- CARE $153,120,000.00
- ERAS N/A
- Revenue This Year
- CARE $10.85
- ERAS N/A
- Revenue Next Year
- CARE $14.12
- ERAS N/A
- P/E Ratio
- CARE $14.27
- ERAS N/A
- Revenue Growth
- CARE 21.78
- ERAS N/A
- 52 Week Low
- CARE $13.61
- ERAS $1.01
- 52 Week High
- CARE $20.53
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- CARE 54.87
- ERAS 73.25
- Support Level
- CARE $18.95
- ERAS $2.21
- Resistance Level
- CARE $19.69
- ERAS $2.65
- Average True Range (ATR)
- CARE 0.39
- ERAS 0.21
- MACD
- CARE -0.08
- ERAS 0.06
- Stochastic Oscillator
- CARE 52.50
- ERAS 89.39
About CARE Carter Bankshares Inc.
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.